WEKO3
アイテム
{"_buckets": {"deposit": "0026294d-7fc4-4530-9151-ec6a454eeac3"}, "_deposit": {"created_by": 11, "id": "4297", "owners": [11], "pid": {"revision_id": 0, "type": "depid", "value": "4297"}, "status": "published"}, "_oai": {"id": "oai:shiga-med.repo.nii.ac.jp:00004297", "sets": ["79"]}, "author_link": ["8708", "675", "674"], "item_4_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "7", "bibliographicPageEnd": "823", "bibliographicPageStart": "814", "bibliographicVolumeNumber": "45", "bibliographic_titles": [{}, {"bibliographic_title": "Biological \u0026 pharmaceutical bulletin", "bibliographic_titleLang": "en"}]}]}, "item_4_creator_3": {"attribute_name": "著者別名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "野田, 哲史"}], "nameIdentifiers": [{"nameIdentifier": "674", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60865707", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=60865707"}]}, {"creatorNames": [{"creatorName": "森田, 真也"}], "nameIdentifiers": [{"nameIdentifier": "8708", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "20449870", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=20449870"}, {"nameIdentifier": "0000-0003-4079-707X", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0003-4079-707X"}]}, {"creatorNames": [{"creatorName": "寺田, 智祐"}], "nameIdentifiers": [{"nameIdentifier": "675", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10324641", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=10324641"}]}]}, "item_4_description_14": {"attribute_name": "フォーマット", "attribute_value_mlt": [{"subitem_description": "pdf", "subitem_description_type": "Other"}]}, "item_4_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Oral multi-kinase inhibitors have transformed the treatment landscape for various cancer types and provided significant improvements in clinical outcomes. These agents are mainly approved at fixed doses, but the large inter-individual variability in pharmacokinetics and pharmacodynamics (efficacy and safety) has been an unsolved clinical issue. For example, certain patients treated with oral multi-kinase inhibitors at standard doses have severe adverse effects and require dose reduction and discontinuation, yet other patients have a suboptimal response to these drugs. Consequently, optimizing the dosing of oral multi-kinase inhibitors is important to prevent over-dosing or under-dosing. To date, multiple studies on the exposure-efficacy/toxicity relationship of molecular targeted therapy have been attempted for the implementation of therapeutic drug monitoring (TDM) strategies. In this milieu, we recently conducted research on several multi-kinase inhibitors, such as sunitinib, pazopanib, sorafenib, and lenvatinib, with the aim to optimize their treatment efficacy using a pharmacokinetic/pharmacodynamic approach. Among them, sunitinib use is an example of successful TDM implementation. Sunitinib demonstrated a significant correlation between drug exposure and treatment efficacy or toxicities. As a result, TDM services for sunitinib has been covered by the National Health Insurance program in Japan since April 2018. Additionally, other multi-kinase targeted anticancer drugs have promising data regarding the exposure-efficacy/toxicity relationship, suggesting the possibility of personalization of drug dosage. In this review, we provide a comprehensive summary of the clinical evidence for dose individualization of multi-kinase inhibitors and discuss the utility of TDM of multi-kinase inhibitors, especially sunitinib, pazopanib, sorafenib, and lenvatinib.", "subitem_description_type": "Abstract"}]}, "item_4_description_42": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "Journal Article", "subitem_description_type": "Other"}]}, "item_4_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "The Pharmaceutical Society of Japan"}]}, "item_4_publisher_34": {"attribute_name": "別言語の出版者", "attribute_value_mlt": [{"subitem_publisher": "日本薬学会"}]}, "item_4_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "35786588", "subitem_relation_type_select": "PMID"}}]}, "item_4_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1248/bpb.b21-01098"}], "subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1248/bpb.b21-01098", "subitem_relation_type_select": "DOI"}}]}, "item_4_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2022 The Pharmaceutical Society of Japan "}, {"subitem_rights": "著作権は日本薬学会に帰属"}]}, "item_4_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1347-5215", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "NODA, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "674", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60865707", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=60865707"}]}, {"creatorNames": [{"creatorName": "MORITA, Shin-ya"}], "nameIdentifiers": [{"nameIdentifier": "8708", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "20449870", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=20449870"}, {"nameIdentifier": "0000-0003-4079-707X", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0003-4079-707X"}]}, {"creatorNames": [{"creatorName": "TERADA, Tomohiro"}], "nameIdentifiers": [{"nameIdentifier": "675", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10324641", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=10324641"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2022-07-28"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "hsf.4479.pdf", "filesize": [{"value": "596.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 596400.0, "url": {"label": "hsf.4479", "url": "https://shiga-med.repo.nii.ac.jp/record/4297/files/hsf.4479.pdf"}, "version_id": "04c48270-d48f-4be4-8be7-2e5767623570"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "individualized pharmacotherapy", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "oral multi-kinase inhibitor", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "dose prediction", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "therapeutic drug monitoring", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring."}]}, "item_type_id": "4", "owner": "11", "path": ["79"], "permalink_uri": "http://hdl.handle.net/10422/00013379", "pubdate": {"attribute_name": "公開日", "attribute_value": "2022-07-28"}, "publish_date": "2022-07-28", "publish_status": "0", "recid": "4297", "relation": {}, "relation_version_is_last": true, "title": ["Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring."], "weko_shared_id": -1}
Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring.
http://hdl.handle.net/10422/00013379
http://hdl.handle.net/10422/000133799fec965b-31a7-45b7-8dd8-f4d0eefb5b83
名前 / ファイル | ライセンス | アクション |
---|---|---|
hsf.4479 (596.4 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2022-07-28 | |||||
タイトル | ||||||
タイトル | Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | individualized pharmacotherapy | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | oral multi-kinase inhibitor | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | dose prediction | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | therapeutic drug monitoring | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
NODA, Satoshi
× NODA, Satoshi× MORITA, Shin-ya× TERADA, Tomohiro |
|||||
著者別名 |
野田, 哲史
× 野田, 哲史× 森田, 真也× 寺田, 智祐 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Oral multi-kinase inhibitors have transformed the treatment landscape for various cancer types and provided significant improvements in clinical outcomes. These agents are mainly approved at fixed doses, but the large inter-individual variability in pharmacokinetics and pharmacodynamics (efficacy and safety) has been an unsolved clinical issue. For example, certain patients treated with oral multi-kinase inhibitors at standard doses have severe adverse effects and require dose reduction and discontinuation, yet other patients have a suboptimal response to these drugs. Consequently, optimizing the dosing of oral multi-kinase inhibitors is important to prevent over-dosing or under-dosing. To date, multiple studies on the exposure-efficacy/toxicity relationship of molecular targeted therapy have been attempted for the implementation of therapeutic drug monitoring (TDM) strategies. In this milieu, we recently conducted research on several multi-kinase inhibitors, such as sunitinib, pazopanib, sorafenib, and lenvatinib, with the aim to optimize their treatment efficacy using a pharmacokinetic/pharmacodynamic approach. Among them, sunitinib use is an example of successful TDM implementation. Sunitinib demonstrated a significant correlation between drug exposure and treatment efficacy or toxicities. As a result, TDM services for sunitinib has been covered by the National Health Insurance program in Japan since April 2018. Additionally, other multi-kinase targeted anticancer drugs have promising data regarding the exposure-efficacy/toxicity relationship, suggesting the possibility of personalization of drug dosage. In this review, we provide a comprehensive summary of the clinical evidence for dose individualization of multi-kinase inhibitors and discuss the utility of TDM of multi-kinase inhibitors, especially sunitinib, pazopanib, sorafenib, and lenvatinib. | |||||
書誌情報 |
en : Biological & pharmaceutical bulletin 巻 45, 号 7, p. 814-823, 発行日 2022-07 |
|||||
出版者 | ||||||
出版者 | The Pharmaceutical Society of Japan | |||||
別言語の出版者 | ||||||
出版者 | 日本薬学会 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1347-5215 | |||||
PMID | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | PMID | |||||
関連識別子 | 35786588 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1248/bpb.b21-01098 | |||||
関連名称 | 10.1248/bpb.b21-01098 | |||||
権利 | ||||||
権利情報 | © 2022 The Pharmaceutical Society of Japan | |||||
権利 | ||||||
権利情報 | 著作権は日本薬学会に帰属 | |||||
フォーマット | ||||||
内容記述タイプ | Other | |||||
内容記述 | ||||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal Article |